Trial Profile
Caelyx in Ovarian Cancer: Prevention and Treatment of Infusion Reactions and Palmar-plantar Erythrodysesthesia (PPE)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 May 2022
Price :
$35
*
At a glance
- Drugs Doxorubicin liposomal (Primary)
- Indications Ovarian cancer
- Focus Adverse reactions
- Sponsors Merck Sharp & Dohme Corp.
- 24 Jun 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 24 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 18 Apr 2009 Planned end date changed from 1 Mar 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov